SER
Serina Therapeutics Inc
2.10$
-2.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -26.6% | +21.1% | -1.4% | -30.6% | -9.6% | +0.1% | +32.8% | +38.8% | -44.0% | +292.7% | -5.4% | |
| – | +567.7% | +17.3% | -0.2% | -39.2% | +4.7% | +1.4% | +38.9% | +43.9% | -47.1% | +335.4% | -5.5% | |
| – | +1,819.1% | +14.3% | -30.3% | -47.5% | +15.3% | +16.2% | +41.6% | +42.7% | -64.5% | +702.6% | -6.1% | |
| – | +1,819.1% | +14.3% | -30.3% | -47.5% | +15.3% | +16.2% | +41.6% | +42.7% | -44.6% | +413.4% | -6.1% | |
| – | -19.7% | +14.0% | -21.5% | -72.5% | – | – | – | – | – | – | – | |
| – | – | – | – | – | -6.4% | -6.8% | -2.8% | -6.1% | -5.6% | – | – | |
| – | -5.2% | -5.4% | -5.7% | -5.9% | – | – | – | – | – | – | – | |
| – | +24.7% | +212.2% | +78.7% | -21.5% | -70.8% | -16.8% | +41.0% | +48.3% | -35.4% | +38.4% | -26.8% | |
| – | -55.9% | +895.0% | -10.1% | +7.0% | -82.5% | -0.6% | +51.4% | +146.8% | -59.5% | +77.9% | -40.7% | |
| – | -83.6% | +3,983.2% | +6.5% | -3.7% | -100.0% | – | – | – | -100.0% | – | – | |
| – | -50.5% | +349.1% | -53.8% | +40.9% | -56.1% | +59.7% | +43.6% | +60.1% | -29.3% | +46.4% | -34.3% | |
| – | – | +0.0% | +0.0% | +0.0% | -100.0% | – | – | – | – | +2.2% | +2.6% | |
| – | -51.2% | -204.8% | – | – | – | +165.4% | +5.9% | -2.3% | -102.1% | – | +6.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -85.8% | +158.6% | +264.1% | +5.8% | +0.0% | -9.3% | +2.5% | +3.3% | -1.4% | +18.2% | +36.0% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.